Last checked at 15 Mar 2018 07:00
REDX PHARMA PLC
("Redx" or "the Company")
Redx Pharma to present poster at prestigious American Association for Cancer Research Annual Meeting
Poster shows that lead candidate, RXC004 - a selective, orally bioavailable porcupine inhibitor- enhances immune response in pre-clinical models of cancer
Dosing recently commenced in phase 1/2a clinical trial of RXC004 in patients with hard to treat cancers
Alderley Park, March 15 2018 - Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that the Company's submitted abstract has been accepted for presentation as a poster at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, 14-18 April 2018.
The poster relates to the Company's lead candidate, RXC004, a potent and selective, orally bioavailable porcupine (PORCN) inhibitor, which is currently being investigated in a phase 1/2a clinical trial in patients with hard to treat cancers. It is expected that initial data from the 1a segment of this trial will be available in H2 2018.
Richard Armer, Chief Scientific Officer of Redx Pharma plc, commented, "We are delighted that our abstract has been accepted at such a high profile conference. We are excited by the potential of RXC004 as a treatment for challenging cancers and look forward to announcing the first data from our clinical development programme with this compound."
The abstract will be presented as a poster on 17 April 2018 8.00am - 12.00pm CST, further details below:
Session Category: Immunology
Session Title: Immunomodulatory Agents and Interventions 1
Abstract Title: Porcupine inhibitor RXC004 enhances immune response in pre-clinical models of cancer
Location: McCormick Place South, Exhibit Hall A, Poster Section 32
Poster Board Number: 14
Permanent Abstract Number: 3764
First author: Inder Bhamra
For further information, please contact:
Redx Pharma Plc | T: +44 1625 469 918 |
Iain Ross, Executive Chairman |
|
Cantor Fitzgerald Europe (Nominated Advisor & Broker) | T: +44 20 7894 7000 |
Phil Davies |
|
|
|
WG Partners LLP (Joint Broker) | T: +44 20 3705 9330 |
Claes Spång/ Chris Lee/ David Wilson |
|
|
|
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Stephanie Cuthbert |
|
About Redx Pharma Plc
Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities.